- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00865813
Biopsy Incisional With Trepan in Periocular Lesions
March 18, 2009 updated by: University of Sao Paulo
The purpose of this study was to identify accuracy rates of 2mm punch biopsy technique in diagnosing periocular malignancy.
Study Overview
Detailed Description
In each case, the histology obtained at biopsy was compared with that identified at the time of tumor excision.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- All lesions were initially examined at the slitlamp, after which lesions with malignant characteristics such as texture, size or color alterations asociated with ulceration, prominent borders or elevated contours, irregular borders, telangiectasias or loss of eyelashes were included.
Exclusion Criteria:
- Lesions with not malignant characteristics
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Punch Biopsy
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
accuracy, positive predictive value, negative predictive value, sensitivity, specificity
Time Frame: In each case, the histology obtained at biopsy was compared with that identified at the time of tumor excision.
|
In each case, the histology obtained at biopsy was compared with that identified at the time of tumor excision.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rachel C Carneiro, University of Sao Paulo - Hospital das Clinicas
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (Anticipated)
October 1, 2009
Study Completion (Anticipated)
December 1, 2009
Study Registration Dates
First Submitted
March 18, 2009
First Submitted That Met QC Criteria
March 18, 2009
First Posted (Estimate)
March 19, 2009
Study Record Updates
Last Update Posted (Estimate)
March 19, 2009
Last Update Submitted That Met QC Criteria
March 18, 2009
Last Verified
March 1, 2009
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 1143/07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumor
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Avelos Therapeutics Inc.RecruitingSolid Tumor | Solid Tumor Cancer | Solid Tumor, Adult | Solid Tumor, Unspecified, Adult | Tumor, Solid | Solid Tumor in Advanced Stage | Solid Tumors Refractory to Standard TherapyKorea, Republic of
-
Monopar TherapeuticsAvailableCancer | Solid Tumor | Solid Tumor Cancer | Oncology | uPAR-positive Solid Tumor | Urokinase Plasminogen Activator Receptor-positive Solid TumorUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Australia, Taiwan, United States
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyCompletedSolid Tumor, Adult | Refractory TumorUnited States
Clinical Trials on Punch Biopsy
-
M.D. Anderson Cancer CenterUnited States Department of DefenseCompletedMelanoma | Sarcoma | Breast Cancer | Malignant Female Reproductive System Neoplasm | Genitourinary CancerUnited States
-
Catholic University of the Sacred HeartCompletedOral Lichen Planus | BiopsyItaly
-
Tampere University HospitalOlfactomics OyRecruitingOral Squamous Cell CarcinomaFinland
-
Tampere University HospitalOlfactomics OyRecruiting
-
Ohio State UniversityCompletedCellulitis | PseudocellulitisUnited States
-
Nova Scotia Health AuthorityWithdrawn
-
Duke UniversityTerminated
-
Maastricht University Medical CenterCompletedBasal Cell CarcinomaNetherlands
-
Chandan SenTerminatedWound Leg | Non-Diabetic Patients | Chronic Ulcer Leg/FootUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedGenito-Urinary NeoplasmUnited States